Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | ||
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
| Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | ||
| Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete | ||
| Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | ||
| Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older | Do not reimburse | Complete | ||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete |
Last Updated : May 12, 2024